HOLX vs BDX vs BAX vs IDXX vs DXCM

For growth investors, DexCom, Inc.

(DXCM) is the stronger pick with 15. 6% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate Becton, Dickinson and Company (BDX) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 26.

3x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 74x versus IDEXX Laboratories, Inc. 's 2. 76x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +16.

9%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus BAX's -42. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus Baxter International Inc. 's 1. 37β — meaning BAX is approximately 234% more volatile than HOLX relative to the S&P 500. On balance sheet safety, DexCom, Inc. (DXCM) carries a lower debt/equity ratio of 51% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DexCom, Inc.

(DXCM) is pulling ahead at 15. 6% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: DexCom, Inc. grew EPS 47. 2% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, DXCM leads at 17. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus -8. 5% for Baxter International Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -2. 7% for BAX. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 74x versus IDEXX Laboratories, Inc. 's 2. 76x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Baxter International Inc. (BAX) trades at 9. 2x forward P/E versus 39. 5x for IDEXX Laboratories, Inc. — 30. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDXX: 35. 1% to $773. 13.

In this comparison, BAX (3.

9% yield), BDX (2. 7% yield) pay a dividend. HOLX, IDXX, DXCM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, IDXX: +556. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HOLX is a mid-cap quality compounder stock; BDX is a mid-cap quality compounder stock; BAX is a small-cap income-oriented stock; IDXX is a mid-cap quality compounder stock; DXCM is a mid-cap high-growth stock. BDX, BAX pay a dividend while HOLX, IDXX, DXCM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.